Alice Verdiani

Alice Verdiani

Auto-generated profile, based on publicly available information

Alice Verdiani

Neuroimmunology Unit European Centre for Brain Research, Fondazione Santa Lucia IRCCS Rome Italy

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 December 2021 in Science Immunology
Verified
Journal Article
Open access
GGGisella Guerrera
Gisella Guerrera
MPMario Picozza
Mario Picozza
SDSilvia D’orso
Silvia D’orso
RPRoberta Placido
Roberta Placido
MPMarta Pirronello
Marta Pirronello
GBGiovanna Borsellino
Giovanna Borsellino
SARS-CoV-2 mRNA vaccination induces stem cell memory T cells specific for the virus that persist up to 6 months.

30 December 2021 in bioRxiv
Verified
Preprint
Open access
PDF file
LMLorenzo De Marco
Lorenzo De Marco
SDSilvia D’orso
Silvia D’orso
MPMarta Pirronello
Marta Pirronello
AVAlice Verdiani
Alice Verdiani
ATAndrea Termine
Andrea Termine
GBGiovanna Borsellino
Giovanna Borsellino
Importance: The emergence of the highly contagious Omicron variant of SARS-CoV-2 and the findings of a significantly reduced neutralizing potency of sera from convalescent or vaccinated individuals imposes the study of cellular immunity to predict the degree of immune protection to the yet again new coronavirus. Design: Prospective monocentric observational study. Setting: Conducted between December 20-21 at the Santa Lucia Foundation IRCCS. Participants: 61 volunteers (Mean age 41.62, range 21-62; 38F/23M) with different vaccination and SARS-CoV-2 infection backgrounds donated 15 ml of blood. Of these donors, one had recently completed chemotherapy, and one was undergoing treatment with monoclonal antibodies; the others reported no known health issue. Main Outcome(s) and Measure(s): The outcomes were the measurement of T cell reactivity to the mutated regions of the Spike protein of the Omicron SARS-CoV-2 variant and the assessment of remaining T cell immunity to the spike protein by stimulation with peptide libraries. Results: Lymphocytes from freshly drawn blood samples were isolated and immediately tested for reactivity to the Spike protein of SARS-CoV-2. T cell responses to peptides covering the mutated regions in the Omicron variant were decreased by over 47% compared to the same regions of the ancestral vaccine strain. However, overall reactivity to the peptide library of the full-length protein was largely maintained (estimated 83%). No significant differences in loss of immune recognition were identified between groups of donors with different vaccination and/or infection histories. Conclusions and Relevance: We conclude that despite the mutations in the Spike protein, the SARS-CoV-2 Omicron variant is nonetheless recognized by the cellular component of the immune system. It is reasonable to assume that protection from hospitalization and severe disease is maintained. Key Points: Question: Does the Omicron variant of SARS-CoV-2 escape cellular immunity? Findings: This observational study was performed on 61 vaccinated donors with established immunity to SARS-CoV-2. Cellular responses to the mutated regions of the Omicron Spike protein were detected in 80% of donors. The mutations reduced T cell recognition by 47% compared to the vaccine strain. Reactivity to the whole Spike protein, however, was present in 100% of donors, and the fraction of remaining immunity to SARS-CoV-2 was estimated to be 83%. Meaning: Cellular immunity to the Omicron variant is maintained despite the mutations in its Spike protein, and may thus confer protection from severe COVID-19 in vaccinated individuals.

18 June 2026 in Annals of Neurology
Verified
Journal Article
Open access
MPMarta Pirronello
Marta Pirronello
MPMario Picozza
Mario Picozza
GGGisella Guerrera
Gisella Guerrera
SCSilvia Corbisiero
Silvia Corbisiero
AMAndrea Misiti
Andrea Misiti
LBLuca Battistini
Luca Battistini
Objective: Multiple sclerosis (MS) is a chronic autoimmune disease where B cells play a central pathogenic role. Cladribine, an oral therapy, provides durable benefits by reshaping lymphocyte populations, yet its specific long‐term impact on distinct B‐cell subsets is not fully understood. This study aimed to define cladribine's longitudinal effects on B‐cell subsets and characterize their inflammatory properties. Methods: We conducted a 48‐month longitudinal study of 36 persons with relapsing–remitting MS treated with cladribine who had completed 2 annual treatment cycles, using high‐parameter flow cytometry to track B‐cell subset dynamics. In a parallel cross‐sectional analysis, B cells from 16 untreated patients and 16 healthy donors were profiled for polyfunctional cytokine production granulocyte‐macrophage colony stimulating factor (GM‐CSF), interleukin‐6 (IL‐6), tumor necrosis factor‐α (TNF‐α) and key surface markers. Results: Cladribine induced profound, sustained depletion of memory B cells, with marginal zone‐like (MZ‐like) cells showing the deepest and most persistent loss, alongside reconstitution of transitional and naïve populations. Functionally, MZ‐like B cells were the most potent polyfunctional producers of proinflammatory cytokines and immunoglobulin M (IgM), a capacity significantly enhanced in persons with MS compared to healthy donors, and expressed the highest levels of CD1c and CD1d, consistent with specialization in lipid antigen presentation. Interpretation: MZ‐like B cells are a dominant, polyfunctional inflammatory subset in MS, equipped for non‐canonical lipid antigen presentation and IgM secretion. They represent a preferential pharmacological target of cladribine. Sustained reduction of this pathogenic memory pool, followed by repopulation with less inflammatory B cells, offers a mechanistic basis for cladribine's durable clinical benefit and nominates MZ‐like cells as biomarkers of response and therapeutic targets. ANN NEUROL 2026